Medical University of South Carolina
This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.
Chronic pancreatitis (CP) and chronic pain: CP is a debilitating disease characterized by persistent pancreatic inflammation, irreversible morphological changes (fibrosis) in the pancreas and severe chronic pain. A progressive loss of exocrine and endocrine function occurs during disease progression. The incidence of CP ranges from 1.6 to 23 cases per 100,000 populations per year worldwide and is likely under diagnosed in the general population. CP in the United States results in more than 122,000 outpatient visits and more than 56,000 hospitalizations per year. The poorly understood pathophys…
Inclusion Criteria: 1. Age between 18 and 75 years old, male or female 2. Definite chronic pancreatitis, using M-ANNHEIM criteria 3. Patients who are diagnosed with painful CP for more than 6 months may be constant or may have been waxing and waning/remitting. 4. Baseline Izbicki pain score \> 30 5. Stable dose of opioids for the past 30 days Exclusion criteria: 1. Acute pancreatitis per 2012 revised Atlanta criteria within the last 30 days. The revised Atlanta classification requires that two or more of the following criteria be met for the diagnosis of acute pancreatitis: 1. abdomi…
Autologous bone marrow derived MSCs
Control
Arctuva estimate
Verify or correct the compensation shown for this listing.